Triptorelin acetate

Triptorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. It is also used as therapy in cases of gender dysphoria.

Properties:

Appearance & Physical State: White powder

Density: 1.52g/cm3

Refractive Index: 1.723

Related Prodcuts:

Abaloparatide; Tetracosactide; Thymalfasin; Thymosin alpha 1; Thymosin beta 4; Triptorelin; Vapreotide; Vasopressin; Ziconotide Acetate; Antide; Protirelin; Teduglutide; Eledoisin; Aviptadil; Teriparatide acetate

1: Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016 Feb 17. pii: /j/jpem.ahead-of-print/jpem-2015-0376/jpem-2015-0376.xml. doi: 10.1515/jpem-2015-0376. [Epub ahead of print] PubMed PMID: 26887034.

2: Meattini I, Saieva C, Meacci F, Scotti V, De Luca Cardillo C, Desideri I, Baldazzi V, Mangoni M, Scoccianti S, Detti B, Simontacchi G, Nori J, Orzalesi L, Sanchez L, Casella D, Bernini M, Fambrini M, Bianchi S, Livi L. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin. Future Oncol. 2016 Mar;12(5):625-35. doi: 10.2217/fon.15.357. Epub 2016 Feb 3. PubMed PMID: 26837239.